Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model

References

• EpelbaumRFaraggiDBen-ArieYSurvival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variablesCancer199066112411292205353
   PubMed Web of Science ®Google Scholar
• GregorySATrumperLChemotherapy dose intensity in non-Hodgkin’s lymphoma: is dose intensity an emerging paradigm for better outcomes?Ann Oncol2005161413142415932900
   PubMed Web of Science ®Google Scholar
• HortobagyiGNProgress in systemic chemotherapy of primary breast cancer: an overviewJ Natl Cancer Inst Monogr2001727911773296
   PubMedGoogle Scholar
• KwakLWHalpernJOlshenRAHorningSJPrognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysisJ Clin Oncol199089639772348230
   PubMed Web of Science ®Google Scholar
• MarangoloMBengalaCContePFDose and outcome: the hurdle of neutropeniaOncol Rep20061623324816820898
   PubMed Web of Science ®Google Scholar
• LepageEGisselbrechtCHaiounCPrognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d’Etude des Lymphomes de l’Adulte)Ann Oncol199346516567694634
   PubMed Web of Science ®Google Scholar
• BudmanDRBerryDACirrincioneCTDose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group BJ Natl Cancer Inst199890120512119719081
   PubMed Web of Science ®Google Scholar
• von MinckwitzGRaabGCaputoADoxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupJ Clin Oncol2005232676268515837982
   PubMed Web of Science ®Google Scholar
• BlayneyDWLeBlancMLGroganTDose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)J Clin Oncol2003212466247312829664
   PubMed Web of Science ®Google Scholar
• PfreundschuhMTrumperLKloessMTwo-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLBlood200410462663314982884
   PubMed Web of Science ®Google Scholar
• ShippMANeubergDJanicekMCanellosGPShulmanLNHigh-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin’s lymphoma: a dose-finding pilot studyJ Clin Oncol199513291629238523055
   PubMed Web of Science ®Google Scholar
• DiehlVFranklinJPfreundschuhMStandard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s diseaseN Engl J Med20033482386239512802024
   PubMed Web of Science ®Google Scholar
• SternbergCNde MulderPHSchornagelJHRandomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924J Clin Oncol2001192638264611352955
   PubMed Web of Science ®Google Scholar
• ThatcherNGirlingDJHopwoodPSambrookRJQianWStephensRJImproving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working PartyJ Clin Oncol20001839540410637255
   PubMed Web of Science ®Google Scholar
• BlayneyDWMcGuireBWCruickshankSEJohnsonDHIncreasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin’s lymphomaOncologist20051013814915709216
   PubMed Web of Science ®Google Scholar
• WunderlichAKloessMReiserMPracticability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)Ann Oncol20031488189312796026
   PubMed Web of Science ®Google Scholar
• SchwenkglenksMJackischCConstenlaMNeutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatmentSupport Care Cancer20061490190916622653
   PubMed Web of Science ®Google Scholar
• SienaSSecondinoSGiannettaLCarminatiOPedrazzoliPOptimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapyCrit Rev Oncol Hematol200348S39S4714563520
   PubMed Web of Science ®Google Scholar
• KudererNMDaleDCCrawfordJCoslerLELymanGHMortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer20061062258226616575919
   PubMed Web of Science ®Google Scholar
• DaleDCurrent management of chemotherapy-induced neutropenia: the role of colony-stimulating factorsSemin Oncol2003303914508714
   PubMed Web of Science ®Google Scholar
• JacobsonMALiuRCDaviesDCohenPTHuman immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infectionArch Intern Med1997157182518319290541
   PubMedGoogle Scholar
• Rodriguez-AdrianLJGrazziuttiMLRexJHAnaissieEJThe potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?Clin Infect Dis199826127012789636845
   PubMed Web of Science ®Google Scholar
• MitchellPLMorlandBStevensMCGranulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patientsJ Clin Oncol199715116311709060560
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRMayordomoJITornamiraMVGranulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trialJ Natl Cancer Inst200193313811136839
   PubMed Web of Science ®Google Scholar
• PettengellRGurneyHRadfordJAGranulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trialBlood199280143014361381626
   PubMed Web of Science ®Google Scholar
• CrawfordJDaleDCLymanGHChemotherapy-induced neutropenia: risks, consequences, and new directions for its managementCancer200410022823714716755
   PubMed Web of Science ®Google Scholar
• BegleyCGNicolaNAMetcalfDProliferation of normal human promyelocytes and myelocytes after a single pulse stimulation by purified GM-CSF or G-CSFBlood1988716406452449922
   PubMed Web of Science ®Google Scholar
• LordBIBronchudMHOwensSThe kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivoProc Natl Acad Sci U S A198986949995032480603
   PubMed Web of Science ®Google Scholar
• SouzaLMBooneTCGabriloveJRecombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cellsScience198623261652420009
   PubMed Web of Science ®Google Scholar
• ColottaFReFPolentaruttiNSozzaniSMantovaniAModulation of granulocyte survival and programmed cell death by cytokines and bacterial productsBlood199280201220201382715
   PubMed Web of Science ®Google Scholar
• MackeyMCAprikyanAADaleDCThe rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humansCell Prolif200336273412558658
   PubMed Web of Science ®Google Scholar
• BronchudMHPotterMRMorgensternGIn vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patientsBr J Cancer19885864692458748
   PubMed Web of Science ®Google Scholar
• TanakaHTokiwaTInfluence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the ratCancer Res199050661566191698539
   PubMed Web of Science ®Google Scholar
• BorleffsJCBosschaertMVrehenHMEffect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjectsClin Ther1998207227369737832
   PubMed Web of Science ®Google Scholar
• EricsonSGGaoHGerickeGHLewisLDThe role of polymorphonuclear neutrophils (PMNs) in clearance of granulocyte colony-stimulating factor (G-CSF) in vivo and in vitroExp Hematol199725131313259406990
   PubMed Web of Science ®Google Scholar
• KhwajaACarverJJonesHMPatersonDLinchDCExpression and dynamic modulation of the human granulocyte colony-stimulating factor receptor in immature and differentiated myeloid cellsBr J Haematol1993852542597506564
   PubMed Web of Science ®Google Scholar
• Kotto-KomeACFoxSELuWYangBBChristensenRDCalhounDAEvidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO modelPharmacol Res200450555815082029
   PubMed Web of Science ®Google Scholar
• El OuriaghliFFujiwaraHMelenhorstJJSconocchiaGHenselNBarrettAJNeutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesisBlood20031011752175812393522
   PubMed Web of Science ®Google Scholar
• ShimazakiCUchiyamaHFujitaNSerum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantationExp Hematol199523149715028542937
   PubMed Web of Science ®Google Scholar
• CrawfordJClinical uses of pegylated pharmaceuticals in oncologyCancer Treat Rev200228Suppl A71112173409
   PubMed Web of Science ®Google Scholar
• TanakaHSatake-IshikawaRIshikawaMMatsukiSAsanoKPharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in ratsCancer Res199151371037141712246
   PubMed Web of Science ®Google Scholar
• YangBBLumPKHayashiMMRoskosLKPolyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in ratsJ Pharm Sci2004931367137315067712
   PubMed Web of Science ®Google Scholar
• GabriloveJLAn analysis of current neutropenia therapies, including pegfilgrastimClin Cornerstone20068Suppl 5S19S2817379160
   PubMedGoogle Scholar
• LordBIWoolfordLBMolineuxGKinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF)Clin Cancer Res200172085209011448927
   PubMed Web of Science ®Google Scholar
• GriggASolal-CelignyPHoskinPOpen-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphomaLeuk Lymphoma2003441503150814565651
   PubMed Web of Science ®Google Scholar
• HolmesFAJonesSEO’ShaughnessyJComparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multi-center dose-finding study in women with breast cancerAnn Oncol20021390390912123336
   PubMed Web of Science ®Google Scholar
• SchippingerWHolubRDandachiNBauernhoferTSamoniggHFrequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastimOncology20067029029316899982
   PubMed Web of Science ®Google Scholar
• PintoLLiuZDoanQBernalMDuboisRLymanGComparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trialsCurr Med Res Opin2007232283229517697451
   PubMed Web of Science ®Google Scholar
• EngelCScholzMLoefflerMA computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapyBlood20041042323233115226178
   PubMed Web of Science ®Google Scholar
• ScholzMEngelCLoefflerMModelling Human Granulopoiesis under Poly-chemotherapy with G-CSF SupportJ Math Biol20055039743915614553
   PubMed Web of Science ®Google Scholar
• LohrmannHPSchremlWCytotoxic drugs and the granulopoietic systemNew YorkSpringer-Verlag1982
   Google Scholar
• BarriosLPolettiOHAgustiniMIThe influence of recombinant human granulocyte colony-stimulating factor on granulopoiesis in mice recovering from cyclophosphamide treatmentMethods Find Exp Clin Pharmacol20002227528011031727
   PubMedGoogle Scholar
• BarriosLPolettiOHEffects of filgrastim on granulopoietic cells of mice pretreated with methotrexateBiocell20052971415954462
   PubMed Web of Science ®Google Scholar
• ColemanDFairchildDSchindler-HorvatJMunyakaziLNeumannTASystemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppressionToxicol Sci19984577879848114
   PubMed Web of Science ®Google Scholar
• MolineuxGKinstlerOBriddellBA new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humansExp Hematol1999271724173410641590
   PubMed Web of Science ®Google Scholar
• PospisilMHoferMNetikovaJPretreatment with granulocyte colony-stimulating factor reduces myelopoiesis in irradiated miceRadiat Res199915136336710073675
   PubMed Web of Science ®Google Scholar
• BauhoferACelikIPlaulUWulfHTorossianAEffects of G-CSF and antibiotic prophylaxis in a 2 × 2 factorial design on outcome in septic ratsInflamm Res200453Suppl 2S12612915338063
   PubMed Web of Science ®Google Scholar
• MisakiMUeyamaYTsukamotoGMatsumuraTTiming of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal miceBr J Cancer1998778848899528829
   PubMed Web of Science ®Google Scholar
• YankelevichMGoodellMAKaplanJEfficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kineticsExp Hematol20083691617949891
   PubMed Web of Science ®Google Scholar
• GriggAPRobertsAWRaunowHOptimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteersBlood199586443744458541532
   PubMed Web of Science ®Google Scholar
• BodeyGPBuckleyMSatheYSFreireichEJQuantitative relationships between circulating leukocytes and infection in patients with acute leukemiaAnn Intern Med1966643283405216294
   PubMed Web of Science ®Google Scholar
• IhakaRGentlemanRRa language for data analysis and graphicsJ Comp Graph Stat19965299314
   Google Scholar
• PeturssonSRChervenickPAMegakaryocytopoiesis and granulopoiesis following cyclophosphamideJ Lab Clin Med19821006826947130827
   PubMed Web of Science ®Google Scholar
• YeagerAMLevinFCLevinJEffects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocyte-macrophage-CFC, and peripheral blood cell levelsJ Cell Physiol19821122222287119022
   PubMed Web of Science ®Google Scholar
• ChattaGSPriceTHAllenRCDaleDCEffects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteersBlood199484292329297524759
   PubMed Web of Science ®Google Scholar
• JohnstonECrawfordJBlackwellSRandomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapyJ Clin Oncol2000182522252810893282
   PubMed Web of Science ®Google Scholar
• RibeiroDVeldwijkMRBennerADifferences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastimTransfusion20074796998017524085
   PubMed Web of Science ®Google Scholar
• TanakaHOkadaYKawagishiMTokiwaTPharmacokinetics and pharmacodynamics of recombinant human granulocyte-colony stimulating factor after intravenous and subcutaneous administration in the ratJ Pharmacol Exp Ther1989251119912032481032
   PubMed Web of Science ®Google Scholar
• MukaeHZamfirDEnglishDHoggJCvan EedenSFPolymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor: intravascular behaviorHematol J2000115917111920185
   PubMedGoogle Scholar
• ScholzMEngelCLoefflerMModel-based design of chemotherapeutic regimens that account for heterogeneity in leucopoeniaBr J Haematol200613272373516487172
   PubMed Web of Science ®Google Scholar
• Hematopoietic growth factors: ESMO Recommendations for the applicationAnn Oncol200718Suppl 2ii89ii9117491063
   PubMedGoogle Scholar
• WeissAJLackmanRDInfusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitationsAm J Clin Oncol19972063689020291
   PubMed Web of Science ®Google Scholar
• LokichJSame-day pegfilgrastim and chemotherapyCancer Invest20052357357616305982
   PubMed Web of Science ®Google Scholar
• LokichJJSame day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphomaAm J Clin Oncol20062936136316891862
   PubMed Web of Science ®Google Scholar
• van Der AuweraPPlatzerEXuZXPharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25–8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastimAm J Hematol20016624525111279634
   PubMed Web of Science ®Google Scholar
• GilmoreGLDePasqualeDKFischerBCShadduckRKEnhancement of monocytopoiesis by granulocyte colony-stimulating factor: evidence for secondary cytokine effects in vivoExp Hematol199523131913237589288
   PubMed Web of Science ®Google Scholar
• ZhanYLieschkeGJGrailDDunnARCheersCEssential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected miceBlood1998918638699446646
   PubMed Web of Science ®Google Scholar
• NishiharaMWadaYOgamiKA combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5Eur J Immunol1998288558649541580
   PubMed Web of Science ®Google Scholar
• YamadaTKanekoHIizukaKMatsubayashiYKokaiYFujimotoJElevation of lymphocyte and hematopoietic stem cell numbers in mice transgenic for human granulocyte CSFLab Invest1996743843948780158
   PubMed Web of Science ®Google Scholar
• VanstraelenGFrerePNgirabacuMCWillemsEFilletGBeguinYPegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantationExp Hematol20063438238816543072
   PubMed Web of Science ®Google Scholar